Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule to Present at the 30th Annual Roth Conference on March 12, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Mar. 5, 2018-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, will present at the 30 th Annual Roth Conference on March 12 th , 2018, at 5:00 p.m. PT at the Ritz-Carlton in Dana Point, California .
View HTML
Toggle Summary ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)--Feb. 20, 2018-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter 2017 before the market opens on Monday, March 5, 2018 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , Chief Medical Officer and Head of Research and Development, will present at the Leerink Partners 7 th Annual Global Healthcare Conference on
View HTML
Toggle Summary Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China
Collaboration will expand the clinical development of derazantinib HONG KONG & BURLINGTON, Mass. --(BUSINESS WIRE)-- Roivant Sciences and ArQule, Inc. (NASDAQ: ARQL) today announced the initiation of a collaboration to pursue the development of derazantinib, a pan-FGFR (fibroblast growth factor
View HTML
Toggle Summary ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma
The trial is being conducted with a biomarker assay to identify FGFR2 fusions BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion driven second-line
View HTML
Toggle Summary ArQule Reports Third Quarter 2017 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017. For the quarter ended September 30, 2017 , the Company reported a net loss of $6,666,000 or $0.09 per share,
View HTML
Toggle Summary ArQule Announces $9.5 Million Private Placement of Preferred Stock
The Pontifax Group led this financing with additional participation from an Israeli-based healthcare equity fund Ran Nussbaum , Managing Partner and co-founder of The Pontifax Group , joins ArQule Board BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc.
View HTML
Toggle Summary FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus syndrome. Under the FDA's rare pediatric disease priority review
View HTML
Toggle Summary ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces $15.7 Million Private Placement of Common Stock
Company also raises approximately $4M through unrelated business development activities and other sources during September-October BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.